Recurrent EGFR-mutated non-small cell lung cancer discovered by abnormal mammogram: Adjuvant/frontline metastatic management options

Mehmet Sitki Copur, Rudy Lackner, Paul Rodriguez, Adam J. Horn, Shellie Faris, Thomas Zusag

Research output: Contribution to journalArticlepeer-review

Abstract

Breast metastasis from extramammary malignancy is rare, with a reported incidence rate of 0.4% to 1.3% in the published literature. The primary malignancies that most commonly metastasize to the breast are leukemia, lymphoma, and malignant melanoma. Here, we report a very rare case of metastatic EGFR-mutated non-small cell lung cancer (NSCLC) in the breast detected by screening mammography. The patient had initially been diagnosed with a clinical stage IIIA NSCLC and had been treated with neoadjuvant chemoradiation followed by curative-intent surgery. Several interesting aspects of the case, along with a discussion of evolving adjuvant and frontline metastatic management options in EGFR-mutated NSCLC, will be presented.

Original languageEnglish (US)
Pages (from-to)347-351
Number of pages5
JournalONCOLOGY (United States)
Issue number3409
DOIs
StatePublished - 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Recurrent EGFR-mutated non-small cell lung cancer discovered by abnormal mammogram: Adjuvant/frontline metastatic management options'. Together they form a unique fingerprint.

Cite this